Topic: osteoarthritis

VetStem submits trial data to FDA for canine stem cell therapy

VetStem Biopharma has treated more than 12,000 companion animals with stem cells removed from their own bodies and then reinjected to treat a variety of joint disorders, including osteoarthritis. Although the company has built its business around such “autologous” treatments, its executives have long believed that the real market opportunity lies in “allogeneic,” or off-the-shelf, stem cells.
Dog with arthritis

Can startup PetVivo survive the canine arthritis market?

PetVivo, founded in 2013 and trading over-the-counter, is running out of resources as it gets set to launch an arthritis treatment for dogs. It’s an unenviable position to be in, especially considering how competitive the canine osteoarthritis market is shaping up to be.

Aratana scores third FDA approval of the year

Shares of Aratana Therapeutics rose more than 3% to $9.75 in after-hours trading on August 15, when the company announced that the FDA approved Nocita (bupivacaine), its long-acting injectable drug to relieve pain in dogs after ligament surgery.